ライフサイエンスコーパス: cytotoxic T-lymphocyte

1 substantial reduction in the number of tumor cytotoxic T lymphocytes.

2 nding and presenting immunogenic peptides to cytotoxic T lymphocytes.

3 or NFATc1 controls the cytotoxicity of mouse cytotoxic T lymphocytes.

4 humans that is normally eliminated by CD8(+) cytotoxic T lymphocytes.

5 important for activation and persistence of cytotoxic T lymphocytes.

6 and increased activation of antigen-specific cytotoxic T lymphocytes.

7 nodes and cross-present antigen to activate cytotoxic T lymphocytes.

8 n of infected or transformed cells by CD8(+) cytotoxic T lymphocytes.

9 man pathogen that is kept in check by CD8(+) cytotoxic T lymphocytes.

10 more H-ras mutations and fewer DMBA-specific cytotoxic T lymphocytes.

11 d engagement with their cognate receptors on cytotoxic T lymphocytes.

12 fected cells, thereby evading elimination by cytotoxic T-lymphocytes.

13 ws that NFATc1 binds many genes that control cytotoxic T lymphocyte activity.

14 correlated with the presence of CD8-positive cytotoxic T lymphocytes among tumor cells (P < .01) and

15 Here, we engineer human beta-cell-specific cytotoxic T lymphocytes and demonstrate that T1-IFN augm

16 main effector molecules expressed by CD8(+) cytotoxic T lymphocytes and function to destroy allogene

17 vertebrate immune system and is secreted by cytotoxic T lymphocytes and natural killer cells to help

18 Close proximity between cytotoxic T lymphocytes and tumour cells is required for

19 tributed to the activation of tumor-reactive cytotoxic T lymphocytes and/or natural killer cells.

20 Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed

21 programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) immune checkpo

22 Despite administration of cytotoxic T lymphocyte antigen 4 (CTLA-4) immunoglobulin

23 checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programm

24 action with CD28 and its alternative ligand, cytotoxic T lymphocyte antigen 4 (CTLA-4).

25 which efforts have focused in particular on cytotoxic T lymphocyte antigen 4 (CTLA4) and PD1, both o

26 inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programm

27 ntibodies targeting the checkpoint molecules cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cel

28 death ligand-1 (PD-1/PD-L1), but not through cytotoxic T lymphocyte antigen 4 (CTLA4), was shown to b

29 kers for differentiation (CD127) and anergy (cytotoxic T lymphocyte antigen 4 [CTLA-4] and programmed

30 e been developed include ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 antibody that enhances

31 ell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed

32 ers of regulatory T cells (Tregs), increased cytotoxic T lymphocyte antigen-4 (CTLA-4) expression, an

33 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulator

34 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essentia

35 We evaluated Eomes and coinhibitory cytotoxic T lymphocyte antigen-4 (CTLA4) expression by a

36 New immune checkpoint inhibitors blocking cytotoxic T lymphocyte antigen-4 (CTLA4) or programmed d

37 Moreover, upon engaging cytotoxic T lymphocyte antigen-4 (CTLA4), CD80-expressin

38 provement in response to abatacept, a CTLA4 (cytotoxic T lymphocyte antigen-4)-immunoglobulin fusion

39 nt of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed

40 ssion of programmed death 1 (PD-1) and lower cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression tha

41 on tumor-infiltrating T lymphocytes, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) molecules are

42 umab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4).

43 The dNP2-conjugated cytoplasmic domain of cytotoxic T-lymphocyte antigen 4 (dNP2-ctCTLA-4) negativ

44 pression (programmed cell death 1 [PD-1] and cytotoxic T-lymphocyte antigen 4 [CTLA-4]) was similar t

45 defensin, beta 4A [DEFB4A]) or dermal (IL22, cytotoxic T-lymphocyte antigen 4 [CTLA4], and CCR7) and

46 Neutralization of cytotoxic T-lymphocyte antigen 4 and transforming growth

47 T-cell responses, blocking antibodies (anti-cytotoxic T-lymphocyte antigen 4, anti-programmed death

48 a human monoclonal antibody targeted against cytotoxic T-lymphocyte antigen 4, has shown promise in t

49 of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte antigen 4, Hsp27, and p53 are nov

50 and overexpression of regulatory molecules (cytotoxic T-lymphocyte antigen 4, programmed cell death

51 e assessed age-specific effects of CTLA4-Ig (cytotoxic T-lymphocyte antigen 4-Ig), a fusion protein b

52 ses antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4.

53 ed in a murine tumor xenograft model of anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) immunotherapy

54 tors, programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), respectively,

55 bitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor),

56 nd 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then

57 Anti-cytotoxic T-lymphocyte antigen-4 therapy was associated

58 uded patients, 17 received therapy targeting cytotoxic T-lymphocyte antigen-4, and 85 received monoth

59 Cytotoxic T lymphocytes are effector CD8(+) T cells that

60 IFN-gamma-producing cytotoxic T lymphocytes are essential for host defense a

61 ckpoint therapy that revives tumour-reactive cytotoxic T lymphocytes, are effective in some patients(

62 Cytotoxic T-lymphocyte assay showed that CD8+ T cells fr

63 , such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), dow

64 ived >60 days in anti-CD154 (MR1)-treated or cytotoxic T-lymphocyte associated protein 4 (CTLA4)-Ig-t

65 of immune checkpoint pathways, in particular cytotoxic T-lymphocyte associated protein 4 and programm

66 grammed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4, is e

67 ckpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and

68 in the expression of the inhibitory molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on

69 We found de novo expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on

70 ocking inhibitory immune checkpoints such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or

71 ponsive beige-like anchor protein (LRBA) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) defi

72 nuclear factor kappaB-inducing kinase (NIK), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), B-c

73 med death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as

74 markers, including FOXP3, CD25, Helios, and cytotoxic T lymphocyte-associated antigen 4; and impaire

75 Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), su

76 h in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated antigen-4 increased T-

77 atory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associated antigen-4 was examined

78 y (anti-CTLA4 DVD, where CTLA4 is defined as cytotoxic T lymphocyte-associated antigen-4) possessing

79 T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4.

80 las (TCGA) demonstrate reduced expression of cytotoxic T lymphocyte-associated genes and IFN-gamma-in

81 kpoint blockade with antibodies specific for cytotoxic T lymphocyte-associated protein (CTLA)-4 or pr

82 une checkpoint inhibitory antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and

83 ng the induction of the checkpoint molecules cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and

84 D-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) for

85 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) res

86 s programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), wh

87 3 and immunosuppressive molecules, IL-10 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4).

88 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4):B7-

89 ath protein (PD) 1-PD ligand 1/2 pathway and cytotoxic T lymphocyte-associated protein 4 are currentl

90 ng fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hi

91 gulatory markers IL-10, forkhead box P3, and cytotoxic T lymphocyte-associated protein 4 in the soil

92 ical trials investigating the combination of cytotoxic T lymphocyte-associated protein 4 inhibitors a

93 anti-programmed cell death protein 1 or anti-cytotoxic T lymphocyte-associated protein 4 is currently

94 ojix), a fusion protein that interferes with cytotoxic T lymphocyte-associated protein 4.

95 have been reported, favored by the fact that cytotoxic T lymphocyte-associated protein pathway has an

96 mmune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and

97 ity in vivo, in line with elevated levels of cytotoxic T-lymphocyte-associated 4 (CTLA-4) protein, bu

98 ment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyte-associated antigen 4 (a-CTLA-4) a

99 tance: Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and

100 by negative regulators of T-cell activation, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and

101 D-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] che

102 geted (BRAF or MEK) or an immune checkpoint (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] or

103 tic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 checkpoint i

104 anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) ant

105 Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is

106 pilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) sig

107 and this tolerance was dependent on CTLA-4 (cytotoxic T-lymphocyte-associated antigen-4) signaling.

108 activity, which resulted in up-regulation of cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) and

109 stigated the biophysical interaction between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and

110 Blocking antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and

111 py targeting the immune checkpoint receptors cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and

112 oxp1 and Foxp3 coordinated the regulation of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) exp

113 The mechanism of action of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) rem

114 IM-3), lymphocyte activation gene-3 (LAG-3), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), cl

115 cHL is highly enriched for non-T-regulatory, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-pos

116 treated with monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; an

117 ein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have

118 Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), whi

119 r 2 (TLR2), which regulates the induction of cytotoxic T-lymphocyte-associated protein 4 (CTLA4).

120 Belatacept (cytotoxic T-lymphocyte-associated protein 4 Ig) is an em

121 G1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated protein 4 receptor tha

122 checkpoint blockade established by targeting cytotoxic T-lymphocyte-associated protein 4 with ipilimu

123 e that dual aOX40 (anti-CD134)/aCTLA-4 (anti-cytotoxic T-lymphocyte-associated protein 4) immunothera

124 stigate whether tremelimumab, an anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitor,

125 alpha, interleukin-2, interleukin-7, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), T-cell rec

126 had COPD, with a panel of CD45, CD28, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), tumor necr

127 tion of the autophagic machinery in DCs in a cytotoxic T-lymphocyte-associated protein 4-dependent (C

128 potential treatment, with administration of cytotoxic T-lymphocyte-associated protein 4-Ig reducing

129 These data suggest that cytotoxic T-lymphocyte-associated protein 4-Ig should be

130 NE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) mon

131 checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or p

132 checkpoint blocking (ICB) antibodies against cytotoxic-T-lymphocyte-associated protein 4 or programme

133 window to impede protective immunity through cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4).

134 ration programs through inhibitory receptor, cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4).

135 ia have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte

136 es of differential escape could aid rational cytotoxic T-lymphocyte-based vaccine immunogen selection

137 omplex (MHC) class I molecule HLA-A2 produce cytotoxic T lymphocytes bearing T cell receptors (TCRs)

138 sing the MHC class I molecule HLA-A2 produce cytotoxic T lymphocytes bearing T-cell receptors (TCRs)

139 the new mouse line is an ideal tool to study cytotoxic T lymphocyte biology and to optimize personali

140 Type I IFN supports cytotoxic T lymphocytes by stimulating the maturation of

141 Human CD8(+) cytotoxic T lymphocytes can mediate tumor regression in

142 ed to correlate well with the populations of cytotoxic T lymphocytes (CD8(+)) and T helper (CD4(+)) c

143 y activated CD4(+) T-helper cells and CD8(+) cytotoxic T lymphocyte cells.

144 eradication is accomplishable by recruiting cytotoxic T lymphocytes, concomitant with downregulation

145 These TMPs inhibit cytotoxic T lymphocyte (CTL) activity both in vitro and

146 CMV replication in the same organs where CD4 cytotoxic T lymphocyte (CTL) activity was observed.

147 nced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity.

148 The immunological synapse formed between a cytotoxic T lymphocyte (CTL) and an infected or transfor

149 immunodeficiencies characterized by impaired cytotoxic T lymphocyte (CTL) and natural killer (NK) cel

150 Although cytotoxic T lymphocyte (CTL) control of HLH development

151 e transcription factor T-bet is critical for cytotoxic T lymphocyte (CTL) differentiation, but it is

152 Identification of CD8(+) cytotoxic T lymphocyte (CTL) epitopes has traditionally

153 thogenicity and disease outcome by targeting cytotoxic T lymphocyte (CTL) epitopes in Nef.

154 ing in-house bioinformatics pipelines, since cytotoxic T lymphocyte (CTL) escape can occur at differe

155 to downregulate MHC-I molecules and enhance cytotoxic T lymphocyte (CTL) evasion in human immunodefi

156 n causes the deterioration of virus-specific cytotoxic T lymphocyte (CTL) function and survival.

157 Cytotoxic T lymphocyte (CTL) function as assessed by inf

158 -1 expression, resulting in increased CD8(+) cytotoxic T lymphocyte (CTL) function.

159 t represents an important induction site for cytotoxic T lymphocyte (CTL) immunity to airborne pathog

160 ategies that induce establish optimal CD8(+) cytotoxic T lymphocyte (CTL) memory for pathogens like t

161 elp is required for the generation of CD8(+) cytotoxic T lymphocyte (CTL) memory.

162 ls should induce DSA synthesis but not naive cytotoxic T lymphocyte (CTL) precursors' priming via dir

163 es of clonal proliferation or HIV-1-specific cytotoxic T lymphocyte (CTL) pressure shape the provirus

164 id transcriptional changes that occur during cytotoxic T lymphocyte (CTL) proliferation and different

165 high-resolution mass spectrometry to map the cytotoxic T lymphocyte (CTL) proteome and the effect of

166 ortantly, rapamycin treatment did not impair cytotoxic T lymphocyte (CTL) recognition and killing of

167 An effective cytotoxic T lymphocyte (CTL) response against intracellu

168 g tumour-specific adaptive immunity, such as cytotoxic T lymphocyte (CTL) response, can result in pro

169 s, tissue remodeling, and suppression of the cytotoxic T lymphocyte (CTL) response.

170 s have an activator function that triggers a cytotoxic T lymphocyte (CTL) response.

171 Eliciting highly functional CD8(+) cytotoxic T lymphocyte (CTL) responses against a broad r

172 Cytotoxic T lymphocyte (CTL) responses against the HIV G

173 Therefore, Vif-specific cytotoxic T lymphocyte (CTL) responses and drugs that ma

174 , DTA-1-induced IL-9 promoted tumor-specific cytotoxic T lymphocyte (CTL) responses by enhancing the

175 HIV-specific cytotoxic T lymphocyte (CTL) responses decline following

176 ighlighted the ability of HIV to escape from cytotoxic T lymphocyte (CTL) responses that concurrently

177 fective priming of helper T cells but not of cytotoxic T lymphocyte (CTL) responses.

178 ates have different MxB sensitivities due to cytotoxic T lymphocyte (CTL) selected differences in Gag

179 gnaling modules into complexes that redirect cytotoxic T lymphocyte (CTL) specificity and function in

180 dust mite (HDM) challenge without affecting cytotoxic T lymphocyte (CTL), Th1 cell, or Th17 cell res

181 Cytotoxic T lymphocyte (CTL)-based cancer immunotherapie

182 Vaccines that induce cytotoxic T lymphocyte (CTL)-mediated immune responses c

183 Cytotoxic T lymphocyte (CTL)-mediated killing involves t

184 CD8(+) cytotoxic T lymphocytes (CTL) and natural killer cells a

185 Cytotoxic T lymphocytes (CTL) are a major factor in the

186 Although CD8(+) antitumor cytotoxic T lymphocytes (CTL) are the preferred effector

187 TERT-specific cytotoxic T lymphocytes (CTL) have been detected in the

188 in programmed cell death protein 1 (PD-1) on cytotoxic T lymphocytes (CTL) in colon cancer.

189 of HIV.IMPORTANCE In HIV infection, although cytotoxic T lymphocytes (CTL) play a potentially critica

190 We postulate that enhancing cytotoxic T lymphocytes (CTL) targeting conserved envelo

191 ased gene signature, and the ratio of CD8(+) cytotoxic T lymphocytes (CTL) to CD68(+) macrophages bot

192 understanding of the mechanisms employed by cytotoxic T lymphocytes (CTL) to control tumors will aid

193 eless be efficiently cleared by infiltrating cytotoxic T lymphocytes (CTL) without compromising tumor

194 ed immune responses, notably those of CD8(+) cytotoxic T lymphocytes (CTL).

195 Viral factors (e.g. transmitted cytotoxic T- lymphocyte (CTL) escape mutations) or infan

196 HLA class I-restricted cytotoxic T-lymphocyte (CTL) escape mutations in HIV-1 t

197 mount a large, persistently activated CD8(+) cytotoxic T-lymphocyte (CTL) response against HTLV-I-inf

198 To understand the interplay between host cytotoxic T-lymphocyte (CTL) responses and the mechanism

199 thodology for stimulating strong CD8alpha(+) cytotoxic T-lymphocyte (CTL) responses remains lacking.

200 In advanced age, decreased CD8(+) cytotoxic T-lymphocyte (CTL) responses to novel pathogen

201 unosuppression (RIS), rituximab (from 2000), cytotoxic T-lymphocyte (CTL) therapy (available in 1999-

202 unosuppression (RIS), rituximab (from 2000), cytotoxic T-lymphocyte (CTL) therapy (available in 1999-

203 Cytotoxic-T lymphocyte (CTL) responses to epitopes in al

204 ciated with strong and potent HIV-1-specific cytotoxic-T-lymphocyte (CTL) responses restricted by pro

205 Here we show that CD8(+) T-cell (also called cytotoxic T lymphocytes, CTL) feedback activates the NLR

206 eral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insuff

207 ol: increased infiltration and activation of cytotoxic T lymphocytes (CTLs) and CD103+ cross-presenti

208 a persistent infection, while v2.2 generated cytotoxic T lymphocytes (CTLs) and cleared virus within

209 8-2, facilitate cytolytic granule release by cytotoxic T lymphocytes (CTLs) and natural killer (NK) c

210 effects of adaptive and innate immune cells-cytotoxic T lymphocytes (CTLs) and natural killer (NK) c

211 rved in cytolytic lymphocytes-including CD8+ cytotoxic T lymphocytes (CTLs) and natural killer cells-

212 nce of neutrophil NETs interfering cytolytic cytotoxic T lymphocytes (CTLs) and NK cell contacts with

213 Immunological synapse formation between cytotoxic T lymphocytes (CTLs) and the target cells they

214 Cytotoxic T lymphocytes (CTLs) are highly effective seri

215 Cytotoxic T lymphocytes (CTLs) are thought to arrive at

216 Many pathogens evade cytotoxic T lymphocytes (CTLs) by downregulating HLA mol

217 These therapies are based on the idea that cytotoxic T lymphocytes (CTLs) directly recognize and re

218 Cytotoxic T lymphocytes (CTLs) eliminate infected and ne

219 CD8(+) cytotoxic T lymphocytes (CTLs) eliminate virally infecte

220 apies that boost the anti-tumor responses of cytotoxic T lymphocytes (CTLs) have shown promise; howev

221 ls (FDCs), low frequencies of virus-specific cytotoxic T lymphocytes (CTLs) in B cell follicles, expa

222 e of influenza A virus (IAV)-specific CD8(+) cytotoxic T lymphocytes (CTLs) in heterosubtypic cross-p

223 abody) for in vivo molecular imaging of CD8+ cytotoxic T lymphocytes (CTLs) in response to anti-PD-L1

224 tion and numerical reduction of HBV-specific cytotoxic T lymphocytes (CTLs) in the liver and peripher

225 ive cell transfer utilizing tumour-targeting cytotoxic T lymphocytes (CTLs) is one of the most effect

226 Cytotoxic T lymphocytes (CTLs) kill infected and cancero

227 Cytotoxic T lymphocytes (CTLs) kill target cells by the

228 Failure of cytotoxic T lymphocytes (CTLs) or natural killer (NK) ce

229 Tumor-specific CD8(+) cytotoxic T lymphocytes (CTLs) play a critical role in a

230 Cytotoxic T lymphocytes (CTLs) play an important role in

231 tion of tumor antigen-specific (TA-specific) cytotoxic T lymphocytes (CTLs) present within tumors fro

232 CD8 cytotoxic T lymphocytes (CTLs) rely on rapid reorganizat

233 es show, however, that DC vaccine priming of cytotoxic T lymphocytes (CTLs) requires the activity of

234 o examine how cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTLs) respond to allogeneic ant

235 Cytotoxic T lymphocytes (CTLs) use polarized secretion t

236 of these proteins also occurs from activated cytotoxic T lymphocytes (CTLs) where they have recently

237 Cytotoxic T lymphocytes (CTLs) with strong abilities to

238 study the dynamics of virus replication and cytotoxic T lymphocytes (CTLs) within a metapopulation o

239 virus-specific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells

240 of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemi

241 including studies on tumor-infiltrating CD8+ cytotoxic T lymphocytes (CTLs), have led to new immunoth

242 le cancer cells to evade killing mediated by cytotoxic T lymphocytes (CTLs), we performed genome-wide

243 oviruses can be recognized by HIV-1-specific cytotoxic T lymphocytes (CTLs).

244 ass I (MHC-I) expression to evade killing by cytotoxic T lymphocytes (CTLs).

245 vironment that protects malignant cells from cytotoxic T lymphocytes (CTLs).

246 ions in both transferred OT-1 and endogenous cytotoxic T lymphocytes (CTLs).

247 d cells, latently infected cells, virus, and cytotoxic T lymphocytes (CTLs).

248 nd short-lived effector and memory precursor cytotoxic T lymphocytes (CTLs).

249 UL11 affects the function of virus-specific cytotoxic T lymphocytes (CTLs).

250 ough tumor targeting and specific binding to cytotoxic T lymphocytes (CTLs).

251 d unlike primary breast tumors, they exclude cytotoxic T lymphocytes (CTLs).

252 Cytotoxic T-lymphocytes (CTLs) and natural killer cells

253 Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate becau

254 broad, highly functional cytotoxic T cells (cytotoxic T lymphocytes [CTLs]) against the HIV-1 Gag pr

255 Killer T cells (cytotoxic T lymphocytes, CTLs) maintain immune homoeosta

256 els of let-7 expression, while generation of cytotoxic T lymphocytes depends upon T cell receptor-med

257 only in tristetraprolin-deficient mice after cytotoxic T lymphocyte depletion, but also in WSX-1/tris

258 Natural killer cells and cytotoxic T-lymphocytes deploy perforin and granzymes to

259 utologous, ex vivo expanded, virus-specific, cytotoxic T-lymphocytes derived from HIV-infected patien

260 ptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-ass

261 ate that NFATc1 is an important regulator of cytotoxic T lymphocyte effector functions.NFAT nuclear t

262 et al. (2016) showed that forces exerted by cytotoxic T lymphocytes enhance the function of the pore

263 Four HLA-B51-restricted putative cytotoxic T lymphocyte epitopes were identified, includi

264 nt reservoir also contains a large number of cytotoxic T lymphocyte escape mutants, presenting anothe

265 We addressed the ability of cytotoxic T lymphocytes from 30 untreated HIV-infected s

266 regulatory pathway for IL-27 expression and cytotoxic T lymphocyte function mediated by tristetrapro

267 molecular imaging of PD-L1 and CD8 revealed cytotoxic T lymphocytes in the tumor microenvironment in

268 tic cells maturation and the infiltration of cytotoxic T lymphocytes in tumor.

269 to prevent EC death induced by TNF-alpha and cytotoxic T lymphocytes in vitro.

270 on, and adjunct therapy such as CMV-specific cytotoxic T-lymphocyte infusions.

271 ed the growth of liver metastases, driven by cytotoxic T-lymphocyte-mediated antitumor immunity.

272 attenuates liver carcinogenesis and induces cytotoxic T-lymphocyte-mediated regression of establishe

273 der characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and

274 mour regression that is dependent on neither cytotoxic T lymphocytes nor humoral immune response.

275 lin double knockout) leads to a reduction in cytotoxic T lymphocyte numbers.

276 A public alphabetaTCR is identified from the cytotoxic T lymphocytes of patients with carbamazepine-S

277 Cytotoxic T lymphocytes recognize non-self peptides and

278 of elimination of these cells by either the cytotoxic T lymphocyte response or other immune cell sub

279 which has been shown to effectively mount a cytotoxic T lymphocyte response through enhanced tumor i

280 to erythroblasts and eliciting an effective cytotoxic T lymphocyte response via cDC1s.

281 T lymphocytes, suggesting a robust adaptive cytotoxic T-lymphocyte response may, in part, confer res

282 apes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent

283 one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.

284 he HLA alleles C*03:03/C*03:04 no allogeneic cytotoxic T-lymphocyte responses are detected in vitro.

285 nnate effector natural killer (NK) cells and cytotoxic T-lymphocyte responses to leukemia-associated

286 human activated autoreactive CD8(+) T-cell (cytotoxic T lymphocyte) responses within the islets of p

287 Activation of Nfatc1 (-/-) cytotoxic T lymphocytes showed a defective cytoskeleton

288 d T-cell intracytoplasmic antigen 1-positive cytotoxic T lymphocytes, suggesting a robust adaptive cy

289 y ZMYND8 causes breast cancer cells to evade cytotoxic T-lymphocyte surveillance, which leads to tumo

290 ave also been investigated in detail; CD4(+) cytotoxic T lymphocytes (suspected of promoting disease)

291 Upon contact with antigen-presenting cells, cytotoxic T lymphocytes (T cells) establish a highly org

292 Cytotoxic T lymphocytes (T) and natural killer cells are

293 entiation of naive CD8 T cells into effector cytotoxic T lymphocytes upon antigen stimulation is nece

294 Antigen presentation to cytotoxic T lymphocytes via major histocompatibility com

295 en and interacted directly with infiltrating cytotoxic T lymphocytes, which led to macrophage depleti

296 ticulum, herpes simplex virus is hidden from cytotoxic T lymphocytes, which may contribute to establi

297 nock-ins, which are viable and fertile, have cytotoxic T lymphocytes with endogeneously fluorescent c

298 frequent peripheral antigen-specific CD8(+) cytotoxic T lymphocytes with immune memory than IFA-emul

299 1 upregulation protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor respo

300 od to reveal that sorting the most migratory cytotoxic T lymphocytes yields a pool of cells with enha